Itci stock target
ITCI has been the topic of several other reports. BTIG Research lowered their target price on shares of Intra-Cellular Therapies from $73.00 to $68.00 and set a “buy” rating on the stock in a Intra-Cellular Therapies Inc : ITCI Stock Price Quote at ... Free current stock price quotes and data for Intra-Cellular Therapies Inc (ITCI). Research news, charts, stock market performance and earnings. Analyst Actions: BTIG Research Cuts Price Target on Intra-Cellular Therapies to $68 From $73, Reiterates Buy Rating Intra-Cellular Therapies (NASDAQ:ITCI) Raised to “Hold” at ...
Mar 17, 2020 · The stock was given Buy rating by Jefferies in its report released on August 12, 2019, the day when the price target on the stock was placed at 16. JP Morgan was of a view that ITCI is Overweight in its latest report on February 26, 2018. RBC Capital Mkts thinks that ITCI is worth Outperform rating.
Average Recommendation: Buy, Average Target Price: 43.89. Number of Ratings : 9, Current Quarters Estimate: -0.83. FY Report Date: 12 / 2019, Current Year's 21 Mar 2020 Real-time trade and investing ideas on Intra-Cellular Therapies ITCI from the largest community of traders and $ITCI $40 price target . 4. Intra-Cellular Therapies Inc. (NYSE: ITCI) stock research, profile, news, analyst Buy on Intra-Cellular Therapies, Lowers Price Target to $68 Vick MeyerTue,
Analyst Ratings for Intra-Cellular Ther (ITCI) provide recommendations made by outside industry experts. Barchart provides Analyst Ratings to give you another tool to gauge the possible future performance of a stock. Analyst Ratings are available for US and Canadian equities. Analyst Target Prices. The chart at the top shows a one-year
Intra-Cellular Therapies, Inc. (ITCI) Stock Analysis ... Get breaking news and analysis on Intra-Cellular Therapies, Inc. (ITCI) stock, price quote and chart, trading and investing tools. Intra-Cellular target hiked to $65 at Canaccord Genuity on Drilling Down Into the Volatility in Intra-Cellular ... Mar 04, 2020 · On Tuesday, shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) marked $21.32 per share versus a previous $21.88 closing price. With having a -2.56% loss, an insight into the fundamental values of Intra-Cellular Therapies, Inc., investors would also find a great ally in the technical patterns of the stock movements showed in stock charts.
View Intra-Cellular Therapies Inc. ITCI investment & stock information. Get the latest Intra-Cellular Therapies Inc. ITCI detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.
Intra-Cellular Therapies (NASDAQ:ITCI) Raised to “Hold” at ...
One investment analyst has rated the stock with a sell rating, three have issued a hold rating and nine have given a buy rating to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $33.14. ITCI has been the topic of several analyst reports.
The Wisdom of Taking Profits in Small Biotech Stocks Upon FDA Drug Approval Intra-Cellular price target lowered to $68 from $73 at BTIG. The Fly BTIG analyst Robert Hazlett lowered the firm's price target on Intra-Cellular to $68 from $73 but keeps a Buy rating on the shares. The analyst notes that the 23 Mar 2020 The forecasts give the Tailored Brands Inc. stock a price target range of Intra- Cellular Therapies Inc. (NASDAQ:ITCI), on the other hand, Intra-Cellular Ther stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions.